PMID- 12661796
OWN - NLM
STAT- MEDLINE
DCOM- 20030501
LR  - 20141120
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 57
IP  - 2
DP  - 2003 Mar
TI  - Review of clinical experience with atosiban and the Tractocile Efficacy 
      Assessment Survey in Europe (TREASURE) study protocol.
PG  - 121-7
AB  - A phase IV multinational, multicentre study has been designed--the Tractocile 
      Efficacy Assessment Survey in Europe (TREASURE). The aim is to assess atosiban in 
      the clinical setting, which is associated with fewer restrictions than in phase 
      III trials. Atosiban is to be compared with 'usual care' in women eligible for 
      treatment, and will also be evaluated as deferred or immediate treatment in women 
      who have not yet fulfilled the diagnostic criteria for pre-term labour. Exploring 
      the use of atosiban beyond the normal indications may allow the identification of 
      additional subpopulations of women who will benefit from early treatment. 
      TREASURE will offer data on new diagnostic tools, investigate respiratory 
      distress syndrome according to severity and record the use of antenatal steroids. 
      It is hoped that additional information concerning the subtle differences in 
      clinical practice will broaden our understanding of how to manage pre-term labour 
      and offer the chance to revise treatment guidelines.
FAU - Husslein, P
AU  - Husslein P
AD  - Department of Obstetrics and Gynaecology, University Medical School, Vienna, 
      Austria.
FAU - Quartarolo, J P
AU  - Quartarolo JP
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Tocolytic Agents)
RN  - 081D12SI0Z (atosiban)
RN  - W6S6URY8OF (Vasotocin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Obstetric Labor, Premature/*prevention & control
MH  - Pregnancy
MH  - Prospective Studies
MH  - Tocolytic Agents/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Vasotocin/*analogs & derivatives/*therapeutic use
EDAT- 2003/03/29 05:00
MHDA- 2003/05/02 05:00
CRDT- 2003/03/29 05:00
PHST- 2003/03/29 05:00 [pubmed]
PHST- 2003/05/02 05:00 [medline]
PHST- 2003/03/29 05:00 [entrez]
PST - ppublish
SO  - Int J Clin Pract. 2003 Mar;57(2):121-7.